Optibiotix Health, the York-based life sciences company, has announced that ProBiotix Health, its wholly-owned subsidiary, has signed a licencing agreement with Granja Pocha SA.

The agreement will enable ProBiotix’s patented cholesterol and blood pressure-reducing probiotic strain LPLDL® to be included in a yogurt product in Uruguay, South America.

Steve Prescott, CEO of ProBiotix, said: “We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®’s presence into South America and extends its use into dairy products.

“Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.

“Functional foods like this yogurt containing ProBiotix’s LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods.”